Monoclonal antibody for selectively recognizing carcinogenic mutant KIT ITD and application of monoclonal antibody

The invention discloses a monoclonal antibody for selectively recognizing a carcinogenic mutant KIT ITD and an application of the monoclonal antibody. Selectivity of the antibody to KIT ITD is jointlydetermined by specific sequences of CDRs (complementarity-determining regions) and frame regions in variable regions of a heavy chain and a light chain of the antibody, and the carcinogenic mutant KIT ITD in gastrointestinal stromal tumor can be selectively inhibited. Human-mouse fusion antibodies or humanized antibodies can be prepared on the basis of the variable region sequences and the frameregion sequences of the antibody, and can be used for treating the gastrointestinal stromal tumor of KIT ITD type. 本发明公开了种选择性识别致癌性突变体KIT ITD的单克隆抗体及其应用。所述抗体的重链和轻链的可变区中的高变区(CDRs)和框架区的特定序列共同决定了其对KIT ITD的选择性，可选择性抑制胃肠道间质瘤中致癌性突变体KIT ITD。利用此抗体的可变区序列以及框架区序列，可制备人-鼠融合抗体或者人源化抗体，在临床上用于治疗KIT ITD类型的胃肠道间质瘤。